Abstract: Adiponectin (APN), an adipose tissue-excreted adipokine, plays protective roles in metabolic and cardiovascular diseases. In this study, the effects and mechanisms of APN on biological functions of rat vascular endothelial progenitor cells (VEPCs) were investigated in vitro. After administrating APN in rat VEPCs, the proliferation was measured by methyl thiazolyl tetrazolium (MTT) method, the apoptotic rate was test by Flow cytometry assay, mRNA expression of B-cell lymphoma-2 (Bcl-2) and vascular endothelial growth factor (VEGF) was determined by Real-time reverse transcriptase polymerase chain reaction (RT-PCR), and protein expression of mechanistic target of rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 (pSTAT3) was analyzed by Western Blot. It was suggested that APN promoted the optical density (OD) value of VEPCs, enhanced mRNA expression of Bcl-2 and VEGF, and inhibited cell apoptotic rate. Furthermore, protein expression of pSTAT3 was also increased in the presence of APN. Moreover, APN changed-proliferation, apoptosis and VEGF expression of VEPCs were partially suppressed after blocking the mTOR-STAT3 signaling pathway by the mTOR inhibitor XL388. It was indicated that APN promoted biological functions of VEPCs through targeting the mTOR-STAT3 signaling pathway.
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). However, these results only indicated that APN had the potential to improve vascular functions, but its mechanism remained unclear. Therefore, in this study, we explored the mechanism of APN in biological functions of EPCs from blood vessel, which could provide an effective method in the therapy of vascular associated diseases.
Materials and methods

Cell culture
The rat VEPCs purchased from American Type Culture Collection (ATCC) (BNCC338120, USA) were cultured in Endothelial Cell Growth Medium 2 (EGM-2) BulletKit (Lonza, Basel, Switzerland) supplemented with 10% fetal bovine serum (FBS), and antibiotic-antimycotic solution (Gibco®, Life Technologies, Thermo Fisher Scientific, California, USA). VEPCs were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air.
Treatments
The experiments were randomly divided into the following groups: Control, APN treatment (1 μg/ml),
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XL388 treatment, and APN plus XL388 treatment. XL388 (a specific mTOR inhibitor) was purchased from Santa Cruz Biotechnology (2145 Delaware Ave Santa Cruz, CA, USA ), and APN was purchased from Genepharma (Shanghai, China).
MTT assay
VEPCs at a density of 1.0×10 4 /ml were collected from the cultures and replated into a 96-well plate and underwent different treatments. Cell proliferation was determined using MTT method according to the previous study (Dong et al. 2016) . A microplate reader was used to measure the absorbance at 450 nm (Bio-Rad, Hercules, CA, USA).
Flow cytometry
A total of 2.0×10 4 cells were seeded onto a 96-well plate and 24 h later treated with APN, XL388, and APN plus XL388 for indicated times, then cell apoptotic rate was identified by Flow cytometry according to the manufacturer instructions. Cells were collected after trypsinization, and then fixed in 70% ethanol. After ethanol was removed, the samples were stained with 50 μg/ml fluorescein isothiocyanate (FITC), Annexin V, and propidium iodide (PI) (BD Biosciences, San Jose, CA, USA), respectively. Cell apoptotic rate was evaluated using a FACScan flow cytometry apparatus (BD Biosciences, San Jose, CA, USA).
Western blot analysis
The examination of the protein expression levels of mTOR, STAT3 and pSTAT3 was performed separately using Western blot analysis. Total protein was extracted and the protein concentration was measured according to previously published article (Dong et al. 2016). β-actin was used as an internal control. All antibodies were 7 purchased from Santa Cruz Biotechnology, CA, USA. Band density was quantitated using Image J software.
Gene expression analysis
Expression 
Statistical analysis
Data are presented as the mean ± standard deviation (SD). Student's two-tailed t-test was used to determine the statistical differences between the treatment groups and the control groups. P<0.05 was considered to indicate a statistically significant difference.
Results
APN stimulated the proliferation of VEPCs
The cultured VEPCs were stimulated with APN at dose of 1 μg/ml for 12, 24, 48 and 72 h, and the viability 8 was assessed by MTT assay. The experiments revealed that there was no significance between the control group and the APN-treated group at 12 h (P>0.05). Moreover, after 24 h of culture, APN-stimulated VEPCs had a higher proliferation rate than the non-stimulated VEPCs (P<0.05) (Fig.1) .
APN inhibited the apoptosis of VEPCs
APN at concentration of 1 μg/ml was added into VEPCs to evaluate cell apoptosis by Flow cytometry assay in vitro. Fig.2A) . To reinforce these data, the expression of the apoptosis relative factor Bcl-2 was assayed employing RT-PCR in VEPCs. The results showed that, during 72 h of stimulation, the expression of Bcl-2 in VEPCs was higher in the presence of APN than that in VEPCs without APN stimulation, and there was an obvious significant difference between two groups following 24 h of stimulation (P<0.05) (Fig.2B) .
APN enhanced the expression of VEGF in VEPCs
Using RT-PCR method, the influence of APN on the expression of VEGF in cultured VEPCs was determined at different periods of time. As shown in Fig.3 , VEGF was present in the supernatants of cultured VEPCs at a very low level in the control group. Moreover, the expression level of VEGF in the supernatant of VEPCs was significantly enhanced in a time-dependent manner when treated with APN at concentration of 1 μg/ml (P<0.05).
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APN activated the mTOR-STAT3 signaling pathway in VEPCs
To investigate whether APN regulated the mTOR-STAT3 signaling pathway in VEPCs, protein expression of mTOR, STAT3 and pSTAT3 was measured using Western blot analysis (Fig.4A) . It was noted that, compared with the control group, there was a significant increase in pSTAT3 expression (P<0.05), but there were no changes in the bands of mTOR and STAT3 (P>0.05) in the APN-treated groups (Fig.4B) .
APN regulated biological functions of VEPCs via the mTOR-STAT3 signaling pathway
To validate the role of the mTOR-STAT3 signaling pathway played in the proliferation, apoptosis and VEGF expression of VEPCs, after blocking the signal with inhibitor XL388, we further treated VEPCs with APN at concentration of 1 μg/ml for 48 h. As shown in Fig.5A , protein expression of pSTAT3 in VEPCs was evidently down-regulated following treatment with XL388, suggesting the good inhibitory efficiency of XL388 inhibitor (Fig.5A) . After treated VEPCs with XL388 for 48 h, the proliferation of VEPCs was decreased markedly compared with the groups which was not treated with XL388 (P<0.05). Further, there was no difference between the XL388-treated group and the XL388 plus APN-treated group (P>0.05) (Fig.5B ).
Subsequently, it was observed that APN inhibited the apoptotic rate of VEPCs while inhibitor XL388 promoted it (P<0.05). There was also no difference in the apoptotic rate between the XL388-treated group and the XL388 plus APN-treated group (P>0.05) (Fig.5C) . Additionally, the effect of APN on inducing VEGFs could be attenuated by XL388 the inhibitor of mTOR (P<0.05) (Fig.5D ). Results were presented as mean ± SD. *P<0.05 was considered as significance compared with the control. 
Discussion
